Inspiratory Muscle Training Immediately After Lung Transplantation

Sponsor
Ohio State University (Other)
Overall Status
Recruiting
CT.gov ID
NCT05309551
Collaborator
(none)
90
1
3
31.4
2.9

Study Details

Study Description

Brief Summary

Following lung transplantation (LTX), patients may exhibit respiratory and skeletal muscle weakness that will affect exercise capacity, increase dyspnea and fatigue, limit activities of daily living (ADL) and decrease quality of life.

Inspiratory muscle training (IMT) has been extensively studied in a variety of non-LTX populations and research has shown that IMT improves exercise capacity, diaphragmatic thickness, and reduced dyspnea during activities of daily living and improved quality of life in patients with advanced lung disease.

The aim of this randomized controlled study is to investigate the benefits of providing inspiratory muscle training via use of an inspiratory muscle trainer device in addition to standard physical therapy in the acute phase of rehabilitation following LTX. Patients targeted for enrollment will be those with any type of advanced lung disease requiring LTX with the objective of demonstrating improvements in respiratory muscle recovery, perceived dyspnea, severity of fatigue, and overall functional status following the transplant procedure.

Condition or Disease Intervention/Treatment Phase
  • Device: PowerBreathe Medic- Intervention group
  • Device: Powerbreathe Medic- Placebo group
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
90 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Double (Participant, Outcomes Assessor)
Primary Purpose:
Supportive Care
Official Title:
The Effects of Inspiratory Muscle Training Immediatley After Lung Transplantation: a Randomized Controlled Trial
Actual Study Start Date :
Apr 20, 2022
Anticipated Primary Completion Date :
Dec 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Powerbreathe Medic- Intervention group

Along with standard post-transplant physical therapy, the intervention group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with weekly incremental increases in respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.

Device: PowerBreathe Medic- Intervention group
The resistive load will be readjusted weekly to reach 50% of maximal inspiratory pressure (MIP).
Other Names:
  • POWERBreathe Medic Plus®
  • Sham Comparator: Powerbreathe Medic - Placebo group

    Along with standard post-transplant physical therapy, the placebo group will begin daily respiratory exercise training utilizing the IMT trainer device (POWERbreathe Medic Plus®) with no increase of respiratory load. Patients will be asked to use the IMT device twice per day, 7 days per week, for 8 weeks.

    Device: Powerbreathe Medic- Placebo group
    The inspiratory resistive load will be adjusted to the minimum value of the device (9 cm H2O) during all inspiratory muscle training sessions.
    Other Names:
  • POWERBreathe Medic Plus®
  • No Intervention: Usual care group

    Patients will only participate in standard post-transplant physical therapy.

    Outcome Measures

    Primary Outcome Measures

    1. Change in inspiratory muscle strength: Maximal inspiratory pressure (MIP) measured in cmH2O [The groups will be assessed: Before Lung transplantation, at baseline (immediate post-transplant), 8 weeks, 6 and 12 months after LTX]

      Inspiratory muscle strength will be measured as maximal inspiratory pressure (MIP) using a POWERbreathe® KH2, International Ltd; UK. The MIP is defined as the greatest negative pressure sustained for at least one second by each patient. The patient will be verbally encouraged to perform three to five inspiratory maneuvers at maximal intensity. The maximum value will be used for the analysis.

    2. Change in perceived dyspnea: Modified Medical Research Council Dyspnea Scale [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Modified Medical Research Council Dyspnea Scale (mMRC) will measure dyspnea perceptions during the activities of daily living. A score from 0-4 is used to classify the impact of dyspnea on physical function in patients with respiratory limitations. 0 represents a person who suffers from dyspnea only with strenuous exercise. 4 represents a person who are too breathless to leave the house, or breathless when dressing.

    3. Change in fatigue: Fatigue Severity Scale [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Fatigue Severity Scale (FSS) evaluates fatigue using a nine-item, self-scored questionnaire, which with a visual ranking format ranging from one to seven that quantifies patient-perceived fatigue. Higher composite scores indicate more severe fatigue. An average score of less than 2.8 indicates no fatigue, and more than 6.1 indicates chronic fatigue syndrome.

    4. Change in functional capacity [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Functional capacity will be estimated using the 6-minute walk test according to the American Thoracic Society guidelines. Before and after the test, oxygen saturation (SpO2), heart rate, Modified Dyspnea Borg Scale and walking distance will be recorded

    Secondary Outcome Measures

    1. Change in lung function: Pulmonary Function Test [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Lung function will be measured in accordance with the guidelines of the American Thoracic Society. The following variables will be analyzed: (a) forced vital capacity (FVC, L) and (b) forced expiratory volume in the first second (FEV1, L).

    2. Change in physical performance [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Physical performance test will be evaluated using the Short Physical Performance Battery Test (SPPB) to assess standing balance, walking speed, and chair stands. The corresponding score from each section is determined and compiled for an overall score of 0-12.

    3. Change in lower extremity muscle strength [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Quadriceps strength will be measured with a hand-held dynamometer (HHD, Microfet®, Hogan Health Industries, Inc., UT, USA). At least three measurements will be obtained and the higher knee extensor muscle strength value will be used for the analysis.

    4. Change in grip strength [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Grip strength will be performed using a digital dynamometer. At least three measurements will be obtained and the highest reproducible value will be taken into analysis and related to reference values.

    5. Change in quality of life [The groups will be assessed: Before Lung transplantation, 8 weeks, 6 and 12 months after LTX]

      Heath related quality of life will be measured using the SF-36 questionnaire. The 36-Item Short Form Health Survey questionnaire (SF-36) is a very popular instrument for evaluating Health-Related Quality of Life. The SF-36 measures eight scales: physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH).

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Participant has personally signed and dated informed consent form indicating understanding of all pertinent aspects of the study

    • Active on the waiting list for lung transplantation

    • Able to ambulate pre-transplant (not bed/wheelchair bound) with or without assistive device

    Exclusion Criteria:
    • Already participating in a regular IMT program

    • Impaired cognition with inability to follow commands

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Ohio State University Wexner Medical Center Columbus Ohio United States 43210

    Sponsors and Collaborators

    • Ohio State University

    Investigators

    • Principal Investigator: Cristiane Meirelles, PT, PhD, School of Health and Rehabilitation Sciences- Physical Therapy Division

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Cristiane Meirelles, PT, PhD, Assistat Professor-Clinical, Ohio State University
    ClinicalTrials.gov Identifier:
    NCT05309551
    Other Study ID Numbers:
    • 2021H0310
    First Posted:
    Apr 4, 2022
    Last Update Posted:
    Jul 28, 2022
    Last Verified:
    Jul 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jul 28, 2022